Table 5.
Analysis of factors affecting OS
| Items | Cox’s proportional hazard regression model | |||
|---|---|---|---|---|
|
| ||||
| P value | HR | 95% CI | ||
|
| ||||
| Lower | Higher | |||
| Univariate Cox’s regression | ||||
| Therapy | ||||
| Apatinib | Reference | - | - | - |
| Apatinib plus cTACE | 0.001 | 0.139 | 0.042 | 0.465 |
| Apatinib plus DEB-TACE | <0.001 | 0.059 | 0.016 | 0.220 |
| Age (>60 years vs. ≤60 years) | 0.815 | 1.098 | 0.500 | 2.415 |
| Gender (male vs. female) | 0.143 | 1.847 | 0.812 | 4.202 |
| Wight (>60 kg vs. ≤60 kg) | 0.810 | 1.100 | 0.507 | 2.382 |
| HBV (positive vs. negative) | 0.978 | 1.011 | 0.466 | 2.192 |
| ECOG score (2 vs. 1) | 0.080 | 2.137 | 0.912 | 5.008 |
| Child-Pugh stage (B vs. A) | 0.355 | 1.522 | 0.625 | 3.706 |
| Number of intrahepatic tumors (>3 vs. ≤3) | 0.028 | 2.677 | 1.115 | 6.426 |
| Macroscopic vascular invasion (yes vs. no) | 0.578 | 1.253 | 0.567 | 2.770 |
| Tumor size (>5 cm vs. ≤5 cm) | 0.676 | 1.215 | 0.486 | 3.039 |
| Lymph node metastasis (yes vs. no) | 0.353 | 1.595 | 0.596 | 4.269 |
| Distant metastasis (yes vs. no) | 0.024 | 3.226 | 1.168 | 8.914 |
| TNM stage (IV vs. III) | 0.070 | 2.216 | 0.938 | 5.230 |
| CA199￡ (abnormal vs. normal) | 0.083 | 2.080 | 0.910 | 4.756 |
| Bile duct dilatation (yes vs. no) | 0.432 | 1.383 | 0.616 | 3.104 |
| Biliary drainage (yes vs. no) | 0.989 | 0.993 | 0.365 | 2.700 |
| Previous therapy (yes vs. no) | 0.780 | 0.882 | 0.365 | 2.132 |
| Forward stepwise multivariate Cox’s regression | ||||
| Therapy | ||||
| Apatinib | Reference | - | - | - |
| Apatinib plus cTACE | <0.001 | 0.013 | 0.002 | 0.089 |
| Apatinib plus DEB-TACE | <0.001 | 0.005 | 0.001 | 0.043 |
| ECOG score (2 vs. 1) | <0.001 | 13.185 | 3.368 | 51.625 |
| Child-Pugh stage (B vs. A) | 0.004 | 5.747 | 1.747 | 18.906 |
| Number of intrahepatic tumors (>3 vs. ≤3) | <0.001 | 13.463 | 3.321 | 54.579 |
| Bile duct dilatation (yes vs. no) | 0.025 | 3.116 | 1.152 | 8.429 |
Factors affecting OS were analyzed by univariate and forward stepwise multivariate Cox’s proportional hazard regression model.
￡
normal: CA199 level ≤27.0 U/mL, abnormal: CA199 level >27.0 U/mL.
OS, overall survival; HR, hazard ratio; CI, confidence interval; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; HBV, hepatitis B virus; ECOG, Eastern Co-operative Oncology Group; CA199, carbohydrate antigen 199.